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Background/aim: The increasing prevalence and global spread of difficult-to-treat carbapenem-resistant Acinetobacter baumannii has
become a serious problem. The aim of this study is to investigate the resistance patterns and tigecycline sensitivity of carbapenemresistant A. baumannii strains.
Materials and methods: Acinetobacter strains that were carbapenem-resistant and collected mainly from intensive care units were
included into this study. The antibiotic sensitivity/resistance of the strains to other antibiotics and tigecycline were noted. Presence of
blaOXA-23, blaOXA-48, blaOXA-58, and NDM-1 was investigated by PCR.
Results: In total, 44 carbapenem-resistant A. baumannii strains were detected. In addition, 57% (25/44) showed resistance to netilmicin
and 2% (1/43) to tigecycline. All of the strains were susceptible to colistin. blaOXA-58 was found only in one (2%) strain while blaOXA-23
was found in 14 (32%) strains. All strains were negative for blaOXA-48 and NDM-1.
Conclusion: blaOXA-23 was the main resistance pattern in carbapenem-resistant A. baumannii strains. blaOXA-58 was present only in
one strain and no blaOXA-48 was found. Tigecycline susceptibility is high and it can be a treatment option for a possible combination
therapy of carbapenem-resistant A. baumannii, especially for those for whom colistin is contraindicated because of its toxicity.
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1. Introduction
Acinetobacter baumannii has emerged worldwide as an
important opportunistic nosocomial pathogen, especially
in intensive care unit (ICU) patients (1). Carbapenems
have been widely used to treat serious infections
associated with multidrug-resistant (MDR) A. baumannii,
but carbapenem resistance has been increasingly reported
worldwide (2,3). Because of this emerging resistance, new
treatment options with old antibiotics like colistin and
also recent therapy combinations like with tigecycline are
considered.
Resistance to carbapenem in Acinetobacter species
occurs due to the following mechanisms: beta-lactamase
production, the loss of outer-membrane porins,
overexpression of efflux pumps, penicillin-binding protein
alteration, and carbapenem-hydrolyzing oxacillinases
(4,5). Although metallo-beta-lactamase (MBL) has been
* Correspondence: serifealtun@yahoo.com
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identified in a wide variety of gram-negative species, this
class of enzyme is not common in A. baumannii, in which
the oxacillinases represent the most commonly acquired
carbapenem-hydrolyzing enzymes (6). OXA-58-like and
OXA-23-like carbapenemase-producing strains have been
among the most detected patterns in recent years (7).
A study by the same authors of this paper regarding
resistant gram-negative bacteria was conducted in a
tertiary-care hospital in Turkey. Extended-spectrum
beta-lactamase, AmpC, and MBL were investigated in
more than 70 isolates, which included MDR Escherichia
coli, Klebsiella spp. and Acinetobacter strains (8). After
this study, the study team decided to search for further
properties of the Acinetobacter strains.
The aim of this study is to investigate the molecular
characteristics of carbapenem-resistant A. baumannii
isolates identified in our hospital and also evaluate the
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sensitivity of the strains to other antibiotics for alternative
treatment regimens for future empiric therapy options.
2. Materials and methods
Forty-four carbapenem-resistant A. baumannii strains
collected at the Ankara Training and Research Hospital
having 700 beds between June 2011 and June 2012 were
included in this study. Phenotypic study of the strains was
performed in the same hospital, but genotypic classification
was performed in the microbiology laboratory of Hacettepe
University. Isolates were obtained from tracheal aspirates
(n = 15), urine (n = 13), catheters (n = 6), skin/mucosa (n
= 6), blood (n = 2), cerebrospinal fluid (n = 1), and pleural
fluid (n = 1) samples.
Multidrug resistance in A. baumannii is defined
as nonsusceptibility to ≥1 agent in ≥3 of the
following antimicrobial categories: aminoglycosides,
antipseudomonal
carbapenems,
antipseudomonal
fluoroquinolones, antipseudomonal penicillins, extendedspectrum cephalosporins, folate pathway inhibitors,
penicillins + beta-lactamase inhibitors, polymyxins, and
tetracyclines (8). The antibiotic use of the patients, which
genera the strains belonged to, and the origin of the
clinical specimens were noted. Bacterial identification was
performed with the VITEK 2 system (bioMerieux, France)
with the GN cards, used according to the manufacturer’s
instructions. Susceptibility of the isolates to antimicrobial
agents was tested with AST-N174 cards and gram-negative
identification cards (GNID) in the VITEK 2 system and
confirmed by disk diffusion method according to 2010
CLSI standards.
Although the E-test is recommended to detect
sensitivity to tigecycline, automatized results (e.g., VITEK
2) are used in routine work to start the therapy as soon
as possible until E-test results are available. Since the
hospital laboratory sometimes uses different methods in
testing tigecycline sensitivity, tigecycline sensitivity was
investigated by all three methods: disk diffusion (15 µg,
Bioanalyse, Turkey) method, E-test (bioMerieux), and
automatized system (VITEK 2, bioMerieux). For disk
diffusion, British Society for Antimicrobial Chemotherapy
limits were used (≥24 mm: sensitive, ≤19 mm: resistant).
For the E-test, the following MIC values were used,
according to the US Food and Drug Administration: ≥2
µg/mL: sensitive, 4–6 µg/mL: intermediate, and ≤8 µg/
mL: resistant. For the VITEK 2 system the following
MIC values were used: ≥2 µg/mL: sensitive, 4–6 µg/mL:
intermediate, and ≤8 µg/mL: resistant. Results of disk
diffusion, E-test, and VITEK methods were compared by
Spearman correlation test.
Genes encoding oxacillinases showing carbapenemase
activity like OXA-23, OXA-48, and OXA-58 clusters and
NDM-1 were investigated in all A. baumannii isolates by
polymerase chain reaction (RT-PCR).

Isolation of bacterial DNA was done as described by
Olsvik and Strockbine (9). A single colony of the isolate
was inoculated into 2 mL of Mueller-Hinton broth and
inoculated for 18 h at 37 °C. Cells from broth medium were
harvested by centrifuging for 10 min in a microcentrifuge
at 14,000 rpm. Then cells were resuspended in Tris-EDTA
(TE) buffer (1 mM Tris, pH 7.5, and 0.5 mM EDTA,
pH 8.0) and harvested by centrifuging for 10 min in a
microcentrifuge. The bacterial pellet was then resuspended
in TE buffer. The bacterial pellet was then boiled for 10
min and centrifuged at 10,000 rpm for 10 min, and then
the DNA in the supernatant part was frozen at –80 °C until
use (9).
Amplification reactions were performed in a final
volume of 50 µL, containing 1X reaction buffer; 2.5 mM
MgCl2; 0.2 mM each of dATP, dCTP, dGTP, and dTTP; 0.5
U of Taq DNA polymerase (Thermo Scientific, Lithuania);
30 pM each of primers OXA-23-F (5′-GAT GTG TCA
TAG TAT TCG TCG-3′) and OXA-23 R (5′-TCA CAA
CAA CTA AAA GCA CGT-3′) (10), OXA-48A (5′-TTG
GTG GCA TCG ATT ATC GG-3′) and OXA-48B (5′GAC CAC TTC TTT TGT GAT GGC-3′) (11), OXA58A (5′-CGA TCA GAA TGT TCA AGC GC-3′) and
OXA-58B (5′-ACG ATT CTC CCC TCT GCG C-3′) (12),
and NDM Fm (5′-GGT TTG GCG ATC TGG TTT TC3′) and NDM Rm (5′-CGC AAT GGC TCA TCA CGA
TC-3′) (13) (Fermentas, Thermo Scientific); and 5 µL of
sample DNA. The amplification reactions were performed
in an automated thermal cycler (Flexigene, Techne, UK)
programmed for denaturation at 94 °C for 5 min, 94
°C for 25 s for 30 cycles, annealing at 52 °C for 40 s and
extension at 72 °C for 50 s, and a final extension at 72 °C
for 6 min. PCR products (10 µL of each reaction mixture)
were then separated by electrophoresis in 1.5% agarose
gels with 1X TAE running buffer. After the gels were
stained with ethidium bromide, they were visualized on
a UV transilluminator (Kodak Gel Logic 200, USA) and
photographed. As molecular weight standards, 100 bp and
fx174 were used. Isolates with NDM-1, OXA-58, OXA-48,
and OXA-23 phenotypes showed 621-, 528-, 743-, and
1058-bp bands, respectively. Positive and negative controls
were used except for NDM-1, because the controls were
not available for it.
3. Results
All of the carbapenem-resistant A. baumannii isolates
showed 100% resistance to piperacillin, ciprofloxacin,
ceftazidime, and cefepime. In addition, 57% (25/44) showed
resistance to netilmicin and 2% (1/44) to tigecycline. All of
the strains (100%) were susceptible to colistin.
According to VITEK 2, E-test and disk diffusion
results, tigecycline resistance was detected in 1 (2%), 1
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(2%), and 18 (40%) strains, respectively. The only strain
detected as resistant by E-test was found to be sensitive by
VITEK 2, while the resistant strain by VITEK 2 was found
to be intermediately sensitive by E-test. Eight of 26 (31%)
sensitive strains by E-test were found to be intermediately
sensitive by VITEK 2. A correlation of 46% was detected
between E-test and VITEK 2 results (R = 0.463, P = 0.002)
by Spearman correlation test. No correlation was detected
between disk diffusion and the other tests.
Of the 44 carbapenem-resistant A. baumannii isolates,
14 (32%) carried blaOXA-23 (Figure) and 1 (2%) carried
blaOXA-58. None of them carried blaOXA-48 or blaNDM.
Twelve (86%) of the blaOXA-23 carriers were isolated
from patients in the ICUs (anesthesiology ICU (8.66%),
neurosurgery ICU (1.8%), pediatrics ICU (1.8%), neonate
ICU (1.8%), and surgical ICU (1.8%)), and two of them
from patients in the orthopedics and traumatology clinic.
Characteristics and sample sites of carbapenem-resistant
Acinetobacter strains are given in the Table. Of the patients
from whom blaOXA-23-positive strains were isolated,
nine (64%) had been treated with multiple antibiotics
(including carbapenem) while one (7%) had been treated
with cephalosporins and one (7%) had been treated with
glycopeptides, whereas three of them (21%) had not used
any antibiotics before the A. baumannii strains were
isolated.
The blaOXA-58-positive strain was isolated from a
tracheal aspirate culture of a patient who had been under
quinolone therapy in the anesthesia and reanimation ICU.

Table. Characteristics and sample sites of carbapenem-resistant
Acinetobacter strains (n = 44).
n (%)

Samples, n (%)

blaOXA-23

14 (32)

Tracheal aspirates, 5 (36)
Urine, 3 (20)
Skin/mucosa, 4 (29)
Catheter, 1 (7)
Pleural fluid, 1 (7)

blaOXA-58

1 (2)

Tracheal aspirates, 1 (100)

blaOXA-48

0

NA

blaNDM

0

NA

4. Discussion
There are only limited studies on the presence of
oxacillinase type carbapenemases of carbapenemresistant A. baumannii strains in Turkey, where MDR and
panresistant Acinetobacter is a very common problem.
It may be a threat for other European countries as well
because of globalization and frequent admissions of
foreign patients as a part of health tourism, which has been
growing in the recent years. The growing resistance and
nosocomial spread of bacteria carries a big challenge for
management of the infections caused by A. baumannii.

Figure. Positive strains for OXA-23 gene amplified with PCR. Lane 1: MW marker;
Lanes 2, 4, 7–13: isolates positive for OXA-23 gene; Lanes 3, 5, 6, 14–16: negative for
OXA gene.
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MDR A. baumannii clones are spreading throughout
many different geographic areas and treatment options for
MDR A. baumannii infections are limited in most cases to
carbapenems (14). Carbapenem resistance may be caused
by especially carbapenem-hydrolyzing beta-lactamases
and the OXA-types play an especially major role. OXA
carbapenemases are increasingly encountered worldwide,
especially in nosocomial settings. During 1999 to 2009, A.
baumannii strains carrying the blaOXA-58 carbapenemase
gene predominated among carbapenem-resistant isolates of
this species in the hospital flora in various Mediterranean
countries including Italy, Greece, Lebanon, and Turkey
(15,16). In 2006 two carbapenem-resistant A. baumannii
isolates were blaOXA-23-positive in Ireland (17). Since
2009, isolation of A. baumannii producing the OXA23 carbapenemase has been increasingly reported in
European countries (18,19). Similarly, in our study, OXA23 carbapenemase was the dominant resistant pattern; 32%
of 44 A. baumannii strains were OXA 23 carbapenemasepositive. In another study from Turkey, Gür et al. showed
that genes encoding oxacillinases showing carbapenemase
activity (OXA-23, -24, and -58 clusters) were detected in all
44 carbapenem-resistant isolates among 75 A. baumannii
samples collected in 2006: 26 (59.1%) strains harbored
blaOXA-23-like genes and 18 (40.9%) carried blaOXA-58like genes (7). From another European country, Greece,
which is close to Turkey, Liakopoulos et al. (20) showed in
their study that of 174 carbapenem-resistant A. baumannii
isolates 125 (71.8%) carried blaOXA-23, 48 (27.6%) carried
blaOXA-58, and one (0.6%) was positive for both genes. The
majority of blaOXA-58 carriers (n = 42) were isolated during
2010. Five of the blaOXA-23 carriers were isolated in late 2010
from patients in ICUs. A total of 376 Acinetobacter isolates
were collected prospectively from hospitalized patients at 15
medical centers in Germany during three surveillance studies
conducted over a 5-year period (2005–2009); 25 of them were
nonsusceptible to imipenem and all of them produced OXA58-like or OXA-23-like carbapenemases (21).
After the initial report in Toulouse, France, OXA58-producing A. baumannii isolates have been reported
in several countries around the world, suggesting a wide
distribution (12,22,23). In Europe, OXA-58-producing
A. baumannii has been reported in Greece, Italy, Turkey,
Spain, and Belgium (22–24). In our study only one (2.2%)
of the strains carried OXA-58. From a neighboring
country, Sonrabi et al. (25) studied 62 imipenem-resistant
isolates from the northwest of Iran and showed that 3.2%
carried OXA-58 and 88.7% of the strains carried OXA-23.
Another study from Turkey by Ergin et al. (26) evaluated
100 nonduplicate A. baumannii blood culture isolates and
showed that carbapenem resistance was associated with the
presence of blaOXA-23 (31% of isolates) and blaOXA-58
(23% of isolates) genes. The occurrence of isolates carrying

blaOXA-58 genes increased between 2004 and 2009, but
decreased in 2010. In contrast, isolates with blaOXA-23
genes increased during the 2008–2010 period.
blaOXA-24, blaOXA-40, and blaOXA-143, which have
importance in the epidemiology of Acinetobacter and
antimicrobial resistance, have been kept out of the scope
of our study. This can be considered as a limitation of our
analysis.
A. baumannii has developed resistance to many
conventional treatments and can therefore be very
challenging in terms of treatment options (3,27,28).
Various antimicrobials have been used to treat A.
baumannii infection, including carbapenems, polymyxins,
tetracyclines and glycylcyclines, aminoglycosides,
fluoroquinolones, and various combination therapies. Of
these antimicrobial agents, carbapenems have traditionally
been used as the first-line treatment of choice; however,
rates of resistance to this agent are often high, rendering
treatment ineffective. Polymyxins appear to be effective
for treating A. baumannii infections, with low rates of
resistance, although data from well-designed clinical trials
are lacking (27,28). All of our strains were susceptible
to colistin, and although aminoglycoside resistance was
high, compared with other antibiotics like quinolones, to
which the strains were 100% resistant, they can be still an
option for combination therapy. Tigecycline, although not
approved for serious infections of ICU patients, can be an
option in combination therapies for patients especially
in Acinetobacter-related skin and soft tissue infections.
Jones et al. (29) showed that for Acinetobacter spp.,
applying US Food and Drug Administration tigecycline
breakpoint criteria, tigecycline zone diameters (obtained
by disk diffusion) and MIC results (obtained by broth
microdilution) led to an unacceptable error rate of 23.3%.
Thamlikitkul et al. (30) also found that if an inhibition
zone diameter of ≥19 mm was a breakpoint for tigecycline
susceptibility, only 44.6% of the isolates were susceptible to
tigecycline, which shows a very high level of disagreement
between broth microdilution and E-test results. The disk
diffusion method is not useful for detecting tigecycline
sensitivity of A. baumannii. The E-test is the standard
method but sometimes the results are time-consuming.
E-test and VITEK 2 results are correlated to an extent
in our study and we suggest that VITEK 2 results can be
used when trying to choose an alternative therapy with
tigecycline for treating Acinetobacter infections while
waiting for E-test results.
In conclusion, blaOXA-23 was the main resistance
pattern in carbapenem-resistant A. baumannii strains in
our hospital, like in European countries during 2008 and
2010, and mostly derived from A. baumannii strains of
tracheal aspirates and skin/mucosa specimens. blaOXA-58
was present only in one strain and no blaOXA-48 was
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found. Tigecycline susceptibility is high and it can be a
treatment option for a possible combination therapy of

carbapenem-resistant A. baumannii, especially for those
for whom colistin is contraindicated because of its toxicity.
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